UGG and JW Anderson launch first footwear collaboration
UGG has collaborated with JW Anderson on a footwear collection that reinterprets the brand’s Classic Boot and Tasman silhouettes through loafer-inspired designs, as the footwear label continues to work with designers to bring new perspectives to its signature styles.
Launching on 15 October, the unisex collection comprises two styles: the UGG x JW Anderson Loafer Boot, priced at £380, and the UGG x JW Anderson Loafer, priced at £280.
Both styles feature rounded toes and box-stitching, alongside UGG’s signature materials and cushioning. The designs draw on the traditional penny loafer, combining its details with UGG’s established silhouettes.
The collection is available in three colourways selected by JW Anderson founder Jonathan Anderson: Chestnut, Khaki and Orange.

“UGG boots are instantly recognisable, and I was interested in seeing something so familiar through the lens of JW Anderson,” said Anderson.
He added that the collaboration allowed the brands to experiment with the loafer design, which has featured extensively in JW Anderson’s footwear, bags and ready-to-wear collections.

Musician and producer Dev Hynes, known professionally as Blood Orange, fronts the accompanying campaign. Set in a home environment, the imagery explores everyday routines, with Hynes wearing the footwear across a series of looks styled by Anderson.
The collaboration marks the first between UGG and JW Anderson. The collection will be available from UGG.com, JWAnderson.com, selected UGG and JW Anderson stores, and retailers including Selfridges, The Webster and Lane Crawford.

The launch follows Anderson’s appointment as Creative Director of Dior in 2025, where he oversees the French fashion house’s womenswear, menswear and haute couture collections, after an 11-year tenure at Loewe.
Founded in London in 2008, JW Anderson has built a reputation for designs that reinterpret familiar wardrobe staples. UGG, meanwhile, is owned by Deckers Brands, whose portfolio also includes HOKA and Teva.



